Article

Real-World Outcomes of First-line and Second-line Chemotherapy with Dabrafeniband Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single Center

2026-07-01

Abstract excerpt

<title>Abstract</title> <p>Background BRAF V600E mutation constitutes one of the crucial molecular alterations observed in metastatic colorectal cancer, occurring in roughly 10% of affected patients. This unique molecular subtype is characterized by atypical metastatic dissemination features, dismal long-term clinical prognosis, and substantial interindividual heterogeneity in survival benefits. The purpose of t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3d281ae0-87db-56a2-91dd-ac8f763da95c
DOI: 10.21203/rs.3.rs-9805547/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-World Outcomes of First-line and Second-line Chemotherapy with Dabrafeniband Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single CenterDOI 10.21203/rs.3.rs-9805547/v1Read

Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 StudySemantic proximity Read

Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.Semantic proximity Read

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.Semantic proximity Read

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer-A Case Series Study Target Therapy of BRAF-Mutated mCRC.Semantic proximity Read

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.Semantic proximity Read

Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trialSemantic proximity Read

First-line treatment efficacy and prognostic model in RAS-mutant metastatic colorectal cancer: a real-world study.Semantic proximity Read

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Semantic proximity Read

Oncological Outcomes of Patients with Peritoneal Metastasis–only Colorectal Cancer Treated with First-line Bevacizumab and FOLFIRI through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis–only, and Lung Metastasis–onlySemantic proximity Read

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read